验证列线图用于胃癌D2术后化疗患者选择
本研究纳入2000至2013年D2淋巴结清扫术后pT3-4或淋巴结阳性的胃癌患者1464例,评估已发表列线图的区分度和校准度,并按列线图预测的总生存概率进行风险分层。列线图区分度优于第七版AJCC分期,且F-OX化疗在低危组无生存获益,在中危和高危组可降低死亡风险超过20%。
要点
- F-OX化疗在低危组未改善生存,在中危和高危组降低死亡风险超过20%。
- 列线图可辅助胃癌D2术后个体化决定是否行F-OX化疗。
核心结论
- 列线图可辅助胃癌D2术后个体化决策F-OX化疗。
研究设计与样本
- 纳入2000至2013年D2淋巴结清扫术后pT3-4或淋巴结阳性的胃癌患者1464例。
- 评估已发表列线图的区分度和校准度,并按预测总生存概率进行风险分层。
- 采用log rank检验和逆倾向评分加权Cox回归评估各风险亚组中F-OX的疗效。
主要发现
- F-OX在低危组未与生存改善相关。
临床怎么用
- 对胃癌D2术后pT3-4或淋巴结阳性患者,可使用列线图预测总生存概率进行风险分层。
- 低危组可能不支持常规使用F-OX化疗,中危和高危组可从F-OX化疗中获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: According to some guidelines for the management of gastric cancer, adjuvant chemotherapy is recommended for patients with pT3-4 or node-positive disease. The aim of this study was to define low- and high-risk groups in terms of survival, and to predict the benefit of adjuvant fluoropyrimidine plus oxaliplatin (F-OX) chemotherapy. METHODS: Patients with pT3-4 or node-positive gastric cancer after gastrectomy with D2 lymphadenectomy between 2000 and 2013 were included. The performance of a previously published nomogram was assessed by discrimination and calibration. Patients were stratified into risk groups on the basis of the nomogram-predicted overall survival probability. The efficacy of F-OX within each risk subgroup was assessed using the log rank test and Cox regression analysis weighted by inverse propensity score. RESULTS: Some 1464 patients were included. The nomogram showed better discrimination than the seventh AJCC staging classification (concordance index 0·72 versus 0·68 respectively; P = 0·008) and accurate calibration. F-OX was not associated with improved survival in patients in the low-risk group, whereas it reduced the risk of death by over 20 per cent in the intermediate- and high-risk groups (P = 0·036 and P < 0·001 respectively) (P for interaction = 0·014). CONCLUSION: A nomogram can aid in individualized decision-making regarding the administration of F-OX after gastrectomy for cancer.
引用
- Wang ZX, Li GX, Zhou ZW, et al. Validation of a nomogram for selecting patients for chemotherapy after D2 gastrectomy for cancer. Br J Surg. 2017. PMID: 28449182. doi:10.1002/bjs.10550
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。